Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum91978ArticlesСтатьиResearch ArticleMetabolicheskiy sindrom: terapevticheskie vozmozhnosti i perspektivyМетаболический синдром: терапевтические возможности и перспективыZadionchenkoV. SЗадионченкоВ. СAdashevaT. VАдашеваТ. ВDemichevaO. YuДемичеваО. ЮPoryvkinaO. NПорывкинаО. НМосковский государственный медико-стоматологический университет1509200579VOL 7, NO9 (2005)ТОМ 7, №9 (2005)72573328122021Copyright ©; 2005, Consilium MedicumCopyright ©; 2005, ООО "Консилиум Медикум"2005Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/91978

Интерес врачей разных специальностей к симптомокомплексу, получившему название “метаболический синдром” (МС), все более возрастает по мере изучения этого феномена. Патогенез, клинические проявления, принципы лечения МС остаются предметом исследований и дискуссий в медицинском научном мире. Сегодня распространенность МС можно считать эпидемией – этим недугом страдает около 25% взрослого населения

метаболический синдроминсулинорезистентностьFord E.S et al. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 356–9.Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005;San Diego, California. Presented June 12, 2005.Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.Cleary P, Orchard T, Zinman B et al. Coronary calcification in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort for the DCCT/EDIC study group. Program and abstracts of the American Diabetes Association 63rd Annual Scientific Sessions; June 13–17, 2003;New Orleans, Louisiana.Khaw K.T, Wareham N, Bingham S et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413–20.Hamman R. Late - breaking trials. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California. Presented June 12, 2005.Barclay L. Medscape Medical News. New definition of the metabolic syndrome: a newsmaker interview with Sir George Alberti M.A, D Phil, B.M.B.Ch. Available at: http://www.medscape.com/viewarticle/504382 Accessed July 8, 2005.Lindstrьm J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabet Care 2003; 26: 3230–6.Am. College of Physicians. The effect of diet and exercise or Metformin on the metabolic syndrome. AHJ 2005; 142 (8): 1–42.Dansinger M.L, Gleason J.A, Griffith J.L et al. Research Laboratory, Tufts-New England Medical Center, Boston, Mass 02111 Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. Division of Endocrinology, Diabetes, and Metabolism Atherosclerosis, USA.Targerson J.S. XENDOS – a Unique Advantage Abstract Book Satellite Symp, May 2003, Helsinki.Scheen A. Late breaking clinical trials. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California.Sethi J.K, Vidal-Puid A. Visfatin: the missing link between intra - abdominal obesity and diabetes? Trend Mol Med 2005 Aug; 11 (8): 344–7.Kendall D.M, Kim D, Poon T et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California.Chiasson J.L, Josse R.G, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul 23; 290 (4): 486–94.Califf R.M. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J 2003; 5: 13–8.Hetzel J et al. Rapid effects of Rosiglitazone treatment of endothelial function and inflammatory biomarkers. Departament of Endocrinology and Metabolism, University of Ulm, Germany. 2005. Reprint.Fagerberg B et al. Tesaglitazar, a novel dual peroxisome proliferator - activated receptor alpha/gamma agonist, dose - dependently improves the metabolic abnormalities associated with insulin resistance in a non - diabetic population. Wallenberg Laboratory for cardiovascular research, Sweeden. 2005. Reprint.Diabetes rates and b - cell function in the pioglitazone in prevention of diabetes (PIPOD) study. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10–14, 2005; San Diego, California.Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Hypertens 2003; 21: 1011–53.Punzi H.A et al. Antyhypertensive and Lipid – Lowering Heart Attack Treal Study;Trinity Hypertension Research Institute. Metabolic issues in the Antihypertensive and Lipid- Lowering Heart Attack Treal Study. Curr Hypertens Rep 2004; 6: 106–10.van Zwieten P.A. The metabolic syndrome – a therapeutic challenge. University of Amsterdam. 2005.Mancia G et al. Outcomes with nifedipine GITS of coamilozide in hypertensive diabetes and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 2003; 41: 431–6.HOPE study. N Engl J Med 2000; 342: 145–53.Sun Y, Ratajska A, Weber K.T. Inhibition of angiotensin - converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995; 126: 95–101.Nielsen F.S, Rossing P, Ali S et al. Effects of lisinopril and atenolol on left ventricular mass in hypertensive type 2 (noninsulin - dependent) diabetic patients with diabetic nephropathy (abstract). Am J Hypertens 1994; 7: 40A.Handa S, Hamada M, Ura M et al. Regression of increased left ventricular masses in elderly hypertensive patients on lisinopril as assessed by magnetic resonance imaging. Acad Radiol 1996; 3: 294–9.Kawahara J, Hsieh S.T, Tanaka S et al. Effects of lisinopril on lipid peroxidation, cell membrane fatty acids, and insulin sensitivity in essential hypertension with impaired glucose tolerance (abstract). Am J Hypertens 1994; 7: 23A.Slishko E. Influence of lisinopril on blood coagulation and fibrinolysis in hypertensive patients of different age (abstract). Eur Heart J 1994 Aug; 15 (Suppl.): 195.Gillis C.N, Chen X, Merker M.M. Lisinopril and ramiprilat protection of the vascular endothelium against free radical - induced functional injury. J Pharmacol Exp Ther 1992; 262: 212–6.Virdis A, Mattel P, Ghiadoni L et al. Effect of lisinopril on endothelial function in hypertensive patients (abstract). Am J Hypertens 1995; 8: 178.Reisin E et al. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo - controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypert 1997; Jul 30: 140–5.Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.Lindholm L.H et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a North of Sweden efficacy evalution (ALPINE) study. О Hypertens 2003; 21: 1563–74.Mogensen C.E. New concepts in blood pressure - lowing management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. ОA Human Hypertension. 2005; 19: 15–20.Vitale S et al. “Metabolic effect of Telmisartan and Losartan in Hypertensive patients with Metabolic syndrome.” 2005. Reprint.Бенсон С. и др. Телмисартан – блокатор ангиотензиновых рецепторов, способный стимулировать PPARg - рецепторы. Сб.: Лечение артериальной гипертонии и метаболических нарушений: новые данные. М.: Практика, 2005.Дероза Г. и др. Влияние телмисартана и эпросартана на обмен глюкозы и липидный профиль у больных инсулиннезависимым сахарным диабетом и артериальной гипертонией. Сб.: Лечение артериальной гипертонии и метаболических нарушений: новые данные. М.: Практика, 2005.Розано Г.М. и др. Сравнение влияния телмисартана и лосартана на обмен глюкозы у больных артериальной гипертонией и метаболическим синдромом. Сб.: Лечение артериальной гипертонии и метаболических нарушений: новые данные. М.: Практика, 2005.Opie L.H et al. Old antihypertensives and new diabets. J Hypertens 2004; 22: 1453–8.